지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Backgrounds: Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease (CD) increased prevalence and economic burden. Objectives: This study aimed to investigate drug use pattern in IBD patients in a real world. Methods: National Health Insurance claim data from 2010 to 2014 were used in this population-based study. All IBD patients diagnosed during study period were enrolled. IBD medications included 5-aminosalicylic acid (ASA), glucocorticoid, immunomodulator and anti-tumor necrosis factor-α agent(anti TNF-α). Growth rate of IBD prevalence, prescribed drug classes, duration of drug therapy and medication cost were analyzed. Number and percentage of patients for categorical variables, and mean and median for continuous variables were presented. Results: Total numbers of patients were 131,158 and 57,286 during 5 years, and their annual growth rate were 3.2 and 5.7% for UC and CD. UC and CD were prevalent in the 40-50 (41.2%) and 20-30 age groups (36.0%). About 60% of IBD patients was prescribed any of medications. 5-ASA was the most frequently prescribed, followed by corticosteroid and immunomodulator. Anti TNF-α use was the lowest, but 5 times higher than UC in CD. Combination therapies with different class of drugs were in 29% for UC and 62% for CD. Mean prescription days per patient per year were 306 and 378, and the median medication cost per patient per year was KRW 420,000 (USD 383) and KRW 830,000 (USD755), for UC and CD, respectively. Conclusions: Increasing prevalence of IBD requires further studies to contribute to achieve better clinical outcomes of drug therapy.
목차
등록된 정보가 없습니다.
참고문헌 (29)
참고문헌 신청
Cosnes J / 2002 / Long-term evolution of disease behavior of Crohn's disease / Inflamm Bowel Dis 8:244~250
Solberg IC / 2007 / Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study / Clin Gastroenterol Hepatol 5:1430~1438
Ministry of Health Welfare / Standard for calculating the deductible for the applicant. MOHW Notice No. 2017-171
Kaplan GG / 2017 / Understanding and preventing the global increase of inflammatory bowel disease / Gastroenterology 152:313~321
Ng SC / 2017 / Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies / Lancet 390:2769~2778
Solberg IC / 2007 / Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study / Clin Gastroenterol Hepatol 5:1430~1438
Ministry of Health Welfare / Standard for calculating the deductible for the applicant. MOHW Notice No. 2017-171
Kaplan GG / 2017 / Understanding and preventing the global increase of inflammatory bowel disease / Gastroenterology 152:313~321
Ng SC / 2017 / Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies / Lancet 390:2769~2778
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea
Intestinal research
2016 .01
-
Gastritis Associated with Initially Pediatric Crohn’s Disease andUlcerative Colitis
Pediatric Gastroenterology, Hepatology & Nutrition
2018 .01
-
Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
Gut and Liver
2022 .11
-
Clinical spectrum of elderly-onset inflammatory bowel disease in India
Intestinal research
2023 .04
-
Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior
Intestinal research
2019 .01
-
Surgical management of inflammatory bowel disease in China: a systematic review of two decades
Intestinal research
2016 .01
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Effects of COVID-19 vaccines on patient-reported outcomes in patients with inflammatory bowel disease: a multicenter survey study in Korea
Intestinal research
2024 .07
-
Surgical Strategies of Pediatric IBD through Adult IBD (I): UC
대한외과학회 학술대회 초록집
2022 .11
-
Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia
Intestinal research
2022 .04
-
Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
Journal of Korean Medical Science
2021 .12
-
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal research
2023 .01
-
Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Gut and Liver
2020 .01
-
Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study
Intestinal research
2020 .01
-
Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
Intestinal research
2023 .01
-
Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
Journal of Yeungnam Medical Science
2023 .01
-
Immunological pathogenesis of inflammatory bowel disease
Intestinal research
2018 .01
-
염증장질환의 치료: 5-아미노살리실레이트 및 면역 조절제를 중심으로
대한의사협회지
2021 .09
-
Nutritional approach as therapeutic manipulation in inflammatory bowel disease
Intestinal research
2019 .01
-
Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data
Gut and Liver
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0